Last reviewed · How we verify

COVAX+IIV4; COVAX+PPV23

China National Biotec Group Company Limited · FDA-approved active Biologic

COVAX+IIV4; COVAX+PPV23 is a vaccine combination Biologic drug developed by China National Biotec Group Company Limited. It is currently FDA-approved for COVID-19 prevention (COVAX component), Seasonal influenza prevention (IIV4 component), Pneumococcal disease prevention (PPV23 component).

COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23).

COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23). Used for COVID-19 prevention (COVAX component), Seasonal influenza prevention (IIV4 component), Pneumococcal disease prevention (PPV23 component).

At a glance

Generic nameCOVAX+IIV4; COVAX+PPV23
SponsorChina National Biotec Group Company Limited
Drug classvaccine combination
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

COVAX is an inactivated COVID-19 vaccine that stimulates adaptive immune responses against SARS-CoV-2. When co-administered with IIV4 (inactivated influenza vaccine, 4-valent) or PPV23 (pneumococcal polysaccharide vaccine, 23-valent), these formulations provide simultaneous protection against multiple respiratory pathogens through humoral and cellular immunity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about COVAX+IIV4; COVAX+PPV23

What is COVAX+IIV4; COVAX+PPV23?

COVAX+IIV4; COVAX+PPV23 is a vaccine combination drug developed by China National Biotec Group Company Limited, indicated for COVID-19 prevention (COVAX component), Seasonal influenza prevention (IIV4 component), Pneumococcal disease prevention (PPV23 component).

How does COVAX+IIV4; COVAX+PPV23 work?

COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23).

What is COVAX+IIV4; COVAX+PPV23 used for?

COVAX+IIV4; COVAX+PPV23 is indicated for COVID-19 prevention (COVAX component), Seasonal influenza prevention (IIV4 component), Pneumococcal disease prevention (PPV23 component).

Who makes COVAX+IIV4; COVAX+PPV23?

COVAX+IIV4; COVAX+PPV23 is developed and marketed by China National Biotec Group Company Limited (see full China National Biotec Group Company Limited pipeline at /company/china-national-biotec-group-company-limited).

What drug class is COVAX+IIV4; COVAX+PPV23 in?

COVAX+IIV4; COVAX+PPV23 belongs to the vaccine combination class. See all vaccine combination drugs at /class/vaccine-combination.

What development phase is COVAX+IIV4; COVAX+PPV23 in?

COVAX+IIV4; COVAX+PPV23 is FDA-approved (marketed).

What are the side effects of COVAX+IIV4; COVAX+PPV23?

Common side effects of COVAX+IIV4; COVAX+PPV23 include Injection site pain or swelling, Fever, Fatigue, Myalgia, Headache.

Related